Alzheimer's disease (AD) is the major form of age-related dementia and is characterized by progressive cognitive impairment, the accumulation of extracellular amyloid β-peptide (Aβ), and intracellular hyperphosphorylated tau aggregates in affected brain regions. Tau hyperphosphorylation and accumulation in neurofibrillary tangles is strongly correlated with cognitive deficits, and is apparently a critical event in the dementia process because mutations in tau can cause a tangle-only form of dementia called frontotemporal lobe dementia. Among kinases that phosphorylate tau, glycogen synthase kinase 3β (GSK3β) is strongly implicated in AD pathogenesis. In the present study, we established an ELISA to screen for agents that inhibit GSK3β activity and found that the flavonoid morin effectively inhibited GSK3β activity and blocked GSK3β-induced tau phosphorylation in vitro. In addition, morin attenuated Aβ-induced tau phosphorylation and protected human neuroblastoma cells against Aβ cytotoxicity. Furthermore, treatment of 3xTg-AD mice with morin resulted in reductions in tau hyperphosphorylation and paired helical filament-like immunoreactivity in hippocampal neurons. Morin is a novel inhibitor of GSK3β that can reduce tau pathology in vivo and may have potential as a therapeutic agent in tauopathies.
. Tau proteins are microtubule-associated proteins that are abundantly expressed in neurons of peripheral and central nervous systems, primarily in axons wherein they stabilize microtubules (Pittman et al., 2006) . The tau phosphorylation state influences its ability to bind and stabilize microtubules, with hyperphosphorylation resulting in tau detachment and self-aggregation and microtubule depolymerization (Alonso et al., 1994 (Alonso et al., , 1996 (Alonso et al., , 2001 Luk et al., 2009) . Tau hyperphosphorylation and aggregation is sufficient to cause dementia as demonstrated by individuals with FTD, an inherited form of 'tau only' dementia (van Swieten and Spillantini, 2007) . In AD, the numbers of tau tangle-bearing neurons in vulnerable brain regions such as the hippocampus and frontal cortex have been correlated with cognitive impairment in some studies (Dournaud et al., 1995; Nagy et al., 1995) . The cause of tau pathology in AD is not fully understood, but is believed to result from increased oxidative stress (Mattson et al., 1997; Melov et al., 2007; Steinberg et al., 2004) , perturbed cellular calcium homeostasis (Hartigan and Johnson, 1999; Li et al., 2005; Mattson, 1990) and energy deficits (Clodfelder-Miller et al., 2006) . Altered proteolytic processing of the amyloid precursor protein (APP) and accumulation of extracellular amyloid β-peptide (Aβ) may be important antecedents to tauopathy and neuronal degeneration in AD (Mattson, 2004) . Aggregation of hyperphosphorylated tau protein and deposition of Aβ are the two hallmark lesions of AD (Grundke-Iqbal et al., 1986; Hooper et al., 2008; Iqbal and Grundke-Iqbal, 2008; Kar et al., 2004) .
Glycogen synthase kinase 3β (GSK3β) was originally identified as a regulator of glycogen metabolism and is now known to regulate a diverse range of biological functions (Lee and Kim, 2007) . GSK3β is expressed at high levels in neurons in the brain where it plays important roles in regulating structural and metabolic plasticity; two well-studied substrates of GSK3β in neurons are the transcription factor β-catenin and tau (Soutar et al., 2010) . There is accumulating evidence that GSK3β plays a role in the hyperphosphorylation of tau and the associated memory impairment in AD (Hooper et al., 2008) . GSK3β expression is upregulated in the hippocampus and post-synaptosomal supernatants from AD brain (Blalock et al., 2004; Pei et al., 1997) and in circulating
